Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

477
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

512
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

628
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
628
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

659
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
659
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

550
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frailty in Pulmonary Arterial Hypertension: A Cohort Study.

Annals of the American Thoracic Society·2026
Same author

Association of sleep duration with Alzheimer's disease and cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Batch Effect Correction for Neuroimaging Data with Heterogeneous Spatial Correlations.

bioRxiv : the preprint server for biology·2026
Same author

Rejoinder to the discussion on "INTACT: A method for integration of longitudinal physical activity data from multiple sources".

Biometrics·2026
Same author

An open, fully-processed data resource for studying mood and sleep variability in the developing brain.

Aperture neuro·2026
Same author

INTACT: a method for integration of longitudinal physical activity data from multiple sources.

Biometrics·2026

Related Experiment Video

Updated: Feb 7, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

793

Daily Physical Activity in Pulmonary Arterial Hypertension: Insights From a Multicenter Longitudinal Trial Using

Jasleen Minhas1, Haochang Shou2, Nadine Al-Naamani1

  • 1Division of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.

Chest
|February 5, 2026
PubMed
Summary

Accelerometer data reveals daily physical activity in pulmonary arterial hypertension (PAH) patients correlates with disease severity and predicts clinical worsening. These insights offer a patient-centered view beyond traditional tests.

Keywords:
accelerometryactigraphyoutcomesphysical activitypulmonary arterial hypertensionquality of life

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

948
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Related Experiment Videos

Last Updated: Feb 7, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

793
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

948
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Area of Science:

  • Cardiology
  • Pulmonary Medicine
  • Biomedical Engineering

Background:

  • Pulmonary arterial hypertension (PAH) is a severe condition with high mortality.
  • Traditional assessments like the 6-minute walk distance (6MWD) may not fully represent daily activity in PAH patients.
  • Objective measures of real-world physical activity are needed for better patient assessment.

Purpose of the Study:

  • To determine if accelerometer-measured daily physical activity in PAH patients reflects disease severity, functional status, and long-term outcomes.
  • To explore the relationship between physical activity levels and various clinical and patient-reported outcomes.

Main Methods:

  • The PHANTOM trial enrolled PAH patients who wore accelerometers for 7 days at 4 visits over 12 months.
  • Statistical models analyzed associations between daily activity and demographic, clinical, and environmental factors.
  • Clinical outcomes including 6MWD, quality of life (HRQoL), bone mineral density (BMD), and time to clinical worsening were assessed.

Main Results:

  • Eighty-four PAH patients were enrolled; device adherence was high.
  • Physical activity declined over time and was lower in patients with advanced disease (WHO functional class III) and poorer RV function.
  • Lower daily activity correlated with worse HRQoL, lower 6MWD, reduced BMD, and an increased risk of clinical worsening.

Conclusions:

  • Accelerometer-derived physical activity is a valid indicator of disease severity in PAH.
  • Daily activity metrics are associated with HRQoL, BMD, and predict clinical worsening.
  • Wearable sensor data provides a dynamic, patient-centered complement to traditional PAH assessments.